興齊眼藥股票討論區

The company's high P/S ratio is backed by strong forecasted revenue growth, outpacing the rest of the Pharmaceuticals industry. Investors anticipate this growth, justifying a higher stock price. A significant share price drop is unlikely under these conditions.

Shenyang Xingqi Pharmaceutical's strong financials and high ROE hint at potential long-term stock value increase. Impressive net income growth and efficient earnings reinvestment suggest a positive outlook.

Despite Shenyang Xingqi Pharmaceutical Ltd's weak recent revenue performance, the high P/S ratio points to investors holding stocks, anticipating significant revenue recovery. But with forecasted growth mirrored by the industry, the current ratio may not be sustainable without improved performance.